Ignite Creation Date:
2024-05-06 @ 3:25 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629950
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-28
First Post:
2020-11-11
Brief Title:
Rimegepant in Moderate Plaque-type Psoriasis
Sponsor:
Weill Medical College of Cornell University
Organization:
Weill Medical College of Cornell University
Study Overview
Official Title:
A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis The study medication is rimegepant an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide CGRP receptor This medication rimegepant has been approved by the FDA under the trade name Nurtec for the treatment of acute migraine However rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None